Bioaffinity Technologies Inc's Customers Performance

Name: Bioaffinity Technologies Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

BIAF

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


BIAF's Source of Revenues		During the corresponding time, Bioaffinity Technologies Inc recorded a revenue increase by 18.99 % year on year, sequentially revenue grew by 11.77 %. While revenue at the Bioaffinity Technologies Inc 's corporate clients • List of BIAF Customers

for the same period Bioaffinity Technologies Inc recorded revenue increase by 18.99 % year on year, sequentially revenue grew by 11.77 %.

• List of BIAF Customers

Bioaffinity Technologies Inc's Business Units


Department of Defense Observational Studies	0.07 %	of total Revenue
Diagnostic Research and Development	0.07 %	of total Revenue
Health Care Patient Service	31.37 %	of total Revenue
Histology Service Fees	16.41 %	of total Revenue
Medical Director Fees	1.19 %	of total Revenue
Other Revenues	0.07 %	of total Revenue
Laboratory Services	189.34 %	of total Revenue

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Bioaffinity Technologies Inc's Comment on Sales, Marketing and Customers

The company operates in the global lung cancer diagnostic market. Its product, CyPath® Lung, is a noninvasive test primarily used by physicians for patients with indeterminate small pulmonary nodules. The market includes patients undergoing lung cancer screening, those with incidentally found nodules, and lung cancer survivors undergoing post-treatment surveillance. Key market segments consist of high-risk patients with nodules smaller than 20 mm and cancer survivors. The projected market size for CyPath® Lung is over $4.7 billion by 2030 for indeterminate nodules and approximately $870 million over ten years for survivor surveillance.

Bioaffinity Technologies Inc’s Comment on Sales, Marketing and Customers

BIAF's Stock Performance relative to it's Customers

BIAF's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Bioaffinity Technologies Inc	2.87	5.66	-15.88	57
SUBTOTAL	0.00	0.00	0.00	-

Sources: Bioaffinity Technologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Bioaffinity Technologies Inc’s corporate clients.
For your research, we’ve provided 9 tables on Bioaffinity Technologies Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.